Anti-Aging: How the Longevity Consumer Is Rewriting the Beauty Playbook
Updated: 4 days ago
Executive summary. The anti-aging category is being rebuilt around a consumer who wants to age well rather than look young, and who is willing to pay for evidence. Dermatology-led brands are growing at twice the rate of the wider beauty market, aesthetic procedures have become routine, metabolic drugs are reshaping what consumers ask of their skin, and the buyer base is widening at both ends of the age range. Strategic Revenue Insights estimates the global anti-aging market at USD 75.00 billion in 2025, rising to USD 146.16 billion by 2035 at a 6.90 percent compound annual growth rate. The companies that will capture that growth are the ones that treat anti-aging as a longevity service with clinical proof, not a cosmetic promise. This article sets out five lessons from the brands and clinics moving first, with takeaways for strategy, portfolio, marketing, channels, data and revenue.
The structure of that growth matters more than the headline. Strategic Revenue Insights' Anti-Aging Market research finds that anti-wrinkle products are the dominant product segment, that online retail is the fastest-growing distribution channel, that Generation X and Baby Boomers are the primary consumers while Millennials are an emerging group, and that North America is the largest regional market while Asia Pacific is the fastest growing. The research identifies an aging population, advances in dermatological science, rising disposable income in emerging economies, social media influence, demand for clean and natural formulations, and artificial-intelligence-enabled personalisation as the forces behind the forecast, and regulatory cost, price competition and economic uncertainty as the forces working against it.
The demographic engine behind that forecast is not in doubt. The World Health Organization projects that the number of people aged 60 and over will rise from 1.1 billion in 2023 to 1.4 billion by 2030, when one in six people worldwide will be in that age group, and to 2.1 billion by 2050. Deloitte projects that Americans over 50 will account for 62 cents of every dollar of consumer spending by 2050, up from 56 cents in 2020. What has changed is not the size of the older consumer base but what it wants: McKinsey's Future of Wellness research finds that 84 percent of consumers now call wellness a top priority or important in their daily lives, and that 60 percent rate healthy aging as a top or very important priority. Anti-aging is becoming a subset of longevity, and that reframing is changing who wins.
Why the Anti-Aging Market Is Entering a New Phase
Three structural forces are converging.
Dermatology has become the growth engine of beauty. L'Oréal's 2026 half-year results, reported in July 2026, show group sales of EUR 23.77 billion, up 6.8 percent like for like, while its Dermatological Beauty division grew 10.6 percent, its third consecutive quarter of double-digit growth, at a divisional operating margin of 28.4 percent. The Estée Lauder Companies' fiscal 2026 results, reported in August 2026, show organic sales up 3 percent for the year and 5 percent in the fourth quarter, with skin care up 4 percent led by La Mer, The Ordinary and the Estée Lauder brand. Consumers are moving their anti-aging spend toward brands that look and sound like medicine.
Procedures have become routine. The International Society of Aesthetic Plastic Surgery's Global Survey, released in September 2026, counts nearly 17.9 million surgical and 17.3 million non-surgical procedures performed by plastic surgeons in the survey year, with eyelid surgery the most common surgical procedure for both women and men for the first time, and a 9.2 percent increase in overall volume over four years. Qsight data shows Generation Z's share of the aesthetics patient population rising from 4 percent in 2017 to 10 percent in 2024. The line between skincare and clinic is dissolving, and SRI's research already lists dermal fillers and botulinum toxin, laser aesthetics and radiofrequency devices alongside creams and sunscreens in the same market.
Metabolic drugs are changing the brief. PwC's 2026 survey of GLP-1 users found that 54 percent had been on the medication for more than a year, up from 38 percent in 2024. Rapid weight loss changes facial volume and skin laxity, and a durable population of long-term users is asking the beauty and aesthetics industry for solutions that did not exist as a category three years ago. The consumer who wants to age well now arrives with a metabolic history, a clinic relationship and a demand for proof.
These forces explain SRI's forecast of a market that roughly doubles between 2025 and 2035, with growth concentrated in clinically credible products, in-clinic treatments and the digital channels that connect them.
Five Lessons From the Brands and Clinics Moving First
The brands, clinics and retailers converting anti-aging from a cosmetic category into a longevity business share a recognisable pattern. We have distilled it into five lessons, each followed by a takeaway for a specific leadership function.
Lesson 1: Longevity Has Replaced Anti-Aging as the Category Frame
The most important shift in the category is linguistic before it is commercial. Consumers who rate healthy aging as a priority do not describe themselves as fighting age; they describe themselves as maintaining skin, energy and function for longer. YouGov's 2026 Anti-Aging Report divides adults into three groups: 35 percent who actively prevent, 28 percent who maintain, and 31 percent who are indifferent. The preventers are the commercial core. Nineteen percent of them spend USD 50 or more a month on the category, against 5 percent of maintainers and 2 percent of the indifferent.
That segmentation changes the brand promise. The brands moving first are repositioning from correction to prevention and maintenance, from wrinkle reduction to skin health, and from a single cream to a regimen with measurable outcomes. SRI's research names demand for natural, organic and clean products and advances in dermatological science as parallel drivers; the longevity frame reconciles them, because a consumer who wants to age well wants both evidence and tolerability.
The repositioning also widens the market. A category defined by age excludes the young; a category defined by longevity includes them, and the Generation Z share of aesthetic patients shows they are already arriving.
"Nobody under 40 buys anti-aging. Everybody under 40 is buying longevity. Same molecule, different promise, three times the addressable market."
Takeaway on strategy and brand positioning. Reframe the category around longevity and skin health, not age correction. Build the proposition on prevention and maintenance with measurable outcomes, segment the customer base by behaviour rather than by age, and concentrate investment on the preventer segment that spends most. Audit every product claim, name and campaign for language that defines the customer by decline rather than by goal.
Lesson 2: Dermatology Is Where the Growth and the Margin Are
The numbers from the two largest companies in SRI's competitive landscape tell the story. L'Oréal's Dermatological Beauty division grew 10.6 percent in the first half of 2026 against 6.8 percent for the group, with a divisional margin above 28 percent. Estée Lauder's skin care growth was led by La Mer and The Ordinary, two brands at opposite price points that share a clinical, ingredient-led positioning. Consumers are paying for credibility, and credibility in anti-aging increasingly means a dermatologist's endorsement, a clinical study and an ingredient they can name.
The gap between awareness and use shows how much room remains. YouGov finds that 62 percent of adults have heard of botulinum toxin treatments but only 3 percent have tried one, and that 49 percent are aware of anti-aging skincare while 20 percent have used it. The conversion from awareness to use is where dermatology-led brands excel, because they lower the perceived risk of trying.
SRI's research identifies regulatory hurdles and compliance cost as a central restraint. For dermatology-led brands, that restraint is a moat: the clinical evidence, safety data and regulatory discipline that cost money to build are exactly what the longevity consumer is paying for.
Takeaway on portfolio and innovation. Shift the innovation pipeline toward clinically substantiated, dermatologist-endorsed products and regimens. Fund consumer-facing clinical studies, build or acquire dermocosmetic brands rather than stretching mass brands into clinical claims, and treat regulatory capability as a competitive asset. Measure the portfolio by the share of revenue backed by published evidence.
Lesson 3: The Consumer Is Both Older and Younger Than the Category Assumed
The anti-aging buyer used to be a woman between 45 and 65. SRI's research still names Generation X and Baby Boomers as the primary consumers, and the demographic data supports their spending power. But the market is widening at both ends. Generation Z's share of aesthetic patients has more than doubled since 2017, and Statista reports that nearly 70 percent of Generation Z men in the United States used facial skincare products in 2024. Prevention-minded younger consumers are entering the category a decade earlier than their parents did, and men are entering it for the first time at scale.
At the other end, the over-60 population is growing faster than any other age group and controls a rising share of spending. The World Health Organization's projection of 1.4 billion people aged 60 and over by 2030 is the largest demographic tailwind any consumer category has, and it is concentrated in markets where disposable income is rising.
The brands moving first are building distinct propositions for each cohort rather than stretching one product across all of them: prevention and protection for younger consumers, maintenance and repair for mid-life, and function and comfort for older consumers, with men addressed as a segment rather than an afterthought.
"The anti-aging customer is 24 and buying sunscreen, 44 and buying retinol, and 74 and buying skin barrier repair. They are three customers, and most brands are talking to one."
Takeaway on marketing and customer segmentation. Build cohort-specific propositions, products and channels for prevention-minded younger consumers, mid-life maintainers and older consumers, and treat men as a distinct segment with its own routines and language. Shift media and content toward the entry points for each cohort, from social and clinic referral for the young to pharmacy and dermatology for the old. Measure lifetime value by cohort, not by campaign.
Lesson 4: Products and Procedures Are Converging Into One Journey
SRI's market definition already spans anti-wrinkle creams, sunscreens, dermal fillers, botulinum toxin, lasers, chemical peels and radiofrequency devices, and the company list runs from L'Oréal and Estée Lauder to AbbVie's Allergan Aesthetics and Galderma. The consumer no longer sees a boundary between the counter and the clinic. ISAPS counts more than 35 million procedures a year among plastic surgeons alone, and the fastest-growing patient cohort is the one that also buys the most skincare.
The commercial consequence is that the brands and clinics moving first are designing one customer journey across both. Dermocosmetic brands are sold in clinics as pre- and post-procedure care; clinics are prescribing home regimens that extend the result and the relationship; retailers are adding clinical services; and pharmaceutical aesthetics companies are building consumer brands. GLP-1 users, who now form a durable population with specific needs around facial volume and skin laxity, are the clearest case of a consumer who needs products, procedures and medical oversight in one plan.
SRI's research names pharmacies and dermatology clinics as a distinct distribution channel alongside online retail, specialty stores and mass retail. The convergence is where the channel list becomes a single system.
Takeaway on channels and partnerships. Design the customer journey across products and procedures, not within one. Partner with clinics and dermatology networks for pre- and post-procedure care, build service offerings into retail, and develop propositions for GLP-1 users with medical partners. Measure share of the customer's total anti-aging spend, not share of shelf.
Lesson 5: Data and Personalisation Decide Retention
Online retail is the fastest-growing channel in SRI's research, and personalisation enabled by artificial intelligence is listed as a market driver. The two are linked. A longevity consumer who buys a regimen rather than a product expects it to adapt to their skin, their age, their climate and their treatment history, and the brands that can do that retain customers for years rather than purchases.
The data to do it now exists. Skin analysis through smartphone cameras, in-clinic imaging, ingredient-level preference data, purchase history and, increasingly, biomarkers and metabolic data give brands and clinics the raw material for a personalised plan. The companies moving first are using it to build subscription regimens, to time replenishment, to recommend procedures and to show the customer measurable progress, which is the single most powerful retention tool in a category built on hope.
YouGov's segmentation shows why this matters: the 35 percent of preventers who drive spending are the consumers most likely to track results and most likely to switch if they cannot see them. Personalisation is how a brand proves its promise one customer at a time.
The capabilities that decide who captures this demand are specific:
Clinically substantiated products and regimens with published evidence.
Cohort-specific propositions for prevention, maintenance and repair, including men.
Partnerships that connect products, clinics and medical oversight into one journey.
Personalisation infrastructure that turns skin, purchase and treatment data into adaptive plans.
Regulatory and safety capability that turns compliance cost into consumer trust.
Companies evaluating these competitive dynamics in greater detail can use SRI's Anti-Aging Market analysis to assess product, treatment, demographic, channel and regional segments and the positioning of the leading beauty, dermocosmetic and aesthetics companies.
Takeaway on data and technology. Build a single customer record that spans skin analysis, purchases, treatments and outcomes, and use it to deliver adaptive regimens with visible progress. Invest in diagnostic tools at the point of sale and in the clinic, structure replenishment and subscription around measured results, and treat consent and data governance as part of the brand promise. Measure retention by regimen adherence, not by repeat purchase alone.
Where the Opportunity Is Concentrating
Value is moving toward clinical credibility, convergent journeys and personalised retention.
By product, anti-wrinkle products dominate, with UV absorbers and sunscreens growing as prevention becomes the entry point, and dermal fillers and botulinum toxin gaining share as procedures become routine.
By treatment, laser aesthetics, radiofrequency devices and anti-pigmentation therapy are growing as non-surgical options reach a broader and younger patient base.
By demographic, Generation X and Baby Boomers remain the largest spenders, Millennials are the emerging core, and Generation Z and men are the fastest-growing entrants.
By channel, online retail is the fastest growing, pharmacies and dermatology clinics are the credibility channel, and specialty and mass retail remain the volume base.
By geography, North America is the largest market on consumer awareness and healthcare infrastructure, Asia Pacific is the fastest growing on rising incomes and skincare culture, and Europe is the home of the dermocosmetic model that is now being exported.
At the Horizon: What to Watch Over the Next Three Years
The GLP-1 beauty category. As the population of long-term users grows, the brands and clinics that build credible propositions for weight-loss-related skin and facial changes will define a category that did not exist in 2023.
Clinic consolidation and brand ownership. Watch which beauty companies acquire or partner with clinic networks, and which aesthetics companies build consumer brands. The ownership of the convergent journey is being decided now.
Evidence standards. As regulators tighten claims and consumers demand proof, the gap between brands with clinical evidence and brands with marketing will widen. Expect pricing power to follow evidence.
"The next phase of competition in anti-aging will not be won by the brand with the best campaign. It will be won by the one that can show a 50-year-old customer, on her phone, what her skin looked like a year ago and what it looks like now."
The Strategic Revenue Opportunity
For beauty companies, the task is to move the portfolio toward clinically credible, longevity-framed propositions and to own more of the customer journey as it extends into the clinic. For aesthetics and pharmaceutical companies, the priority is to build consumer relationships that outlast a single procedure. For retailers and clinics, the opportunity is to become the trusted point of diagnosis, advice and personalisation. For investors, the signal is evidence: the brands whose growth is backed by clinical data and dermatologist endorsement are the ones that will hold margin as the category crowds.
Market intelligence turns these questions into decisions. Segment-level sizing shows where spend is concentrating, competitive benchmarking shows where mass brands are exposed and where dermocosmetic and aesthetics players are strong, and regional analysis shows which markets are opening first. This is the path from market signals to strategic insight to revenue impact.
Takeaway on revenue. Treat anti-aging as four revenue pools with different buyers and sales cycles: dermocosmetic products and regimens, in-clinic procedures and devices, prevention-led entry products for younger and male consumers, and personalised subscription services. Each needs its own evidence base and channel. Enter where the consumer already trusts a clinical voice, the purchase repeats, and the result can be measured and shown.
The Next Leg: Preparing for the Journey Ahead
The defining shift in anti-aging is that the consumer has changed the question. They no longer ask how to look younger; they ask how to age well, and they expect proof. That changes the brand, the product, the channel and the pace. The companies moving first are not the ones with the most famous names; they are the ones who have accepted that credibility is the product and have built everything else around it.
The next three years will decide which brands, clinics and platforms own the longevity consumer for the following decade. Decision-makers should reframe the category around longevity, move the portfolio toward clinical evidence, build cohort-specific propositions for a wider and younger customer base, design one journey across products and procedures, and use data to show every customer their own result. Companies evaluating growth opportunities in this market can use Strategic Revenue Insights' Anti-Aging Market report to assess market size, competitive dynamics, regional opportunities and strategic growth priorities.
Related analysis: Fragrances and Perfumes: How Premium Scent Is Building a USD 106.91 Billion Market; Pet Food: How Humanization Is Building a USD 219.6 Billion Market by 2034; Air Purifiers: How Indoor Air Quality Became a Subscription Business.
Frequently Asked Questions
How big is the anti-aging market?
Strategic Revenue Insights estimates the global anti-aging market at USD 75.00 billion in 2025, rising to USD 146.16 billion by 2035 at a 6.90 percent compound annual growth rate.
How is the anti-aging consumer changing?
Consumers increasingly want to age well rather than look young, and they are willing to pay for evidence. Dermatology-led brands, routine aesthetic procedures and metabolic drugs are reshaping what they expect from skin care.
Which anti-aging segments lead?
Anti-wrinkle products are the dominant product segment and online retail is the fastest growing channel. Generation X and Baby Boomers are the primary consumers, with Millennials an emerging group. North America is the largest region and Asia Pacific the fastest growing.
What drives growth in anti-aging?
An aging population, advances in dermatological science, rising incomes in emerging economies, social media, demand for clean formulations and AI-enabled personalisation drive growth, while regulatory cost and price competition work against it.
About the authors: This article was prepared by the Strategic Revenue Insights research team, which combines market intelligence, competitive analysis and strategic advisory for growth-stage, mid-market and enterprise organisations across the consumer goods sector. Sector analyst: Sandeepa Kulkarni, Research Analyst. Our market estimates combine primary research (interviews, surveys and expert panels) with secondary data (industry reports, databases and public disclosures); read more about how Strategic Revenue Insights works. To discuss this market with our analysts, contact our team.
Comments